Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators

Definitions

• the invention relates to pharmaceutical compositions suitable to decrease the number of CD8+ cells containing 7-isopropoxyisoflavone (IPRIFLAVONE) as active ingredient.
• IPRIFLAVONE 7-isopropoxyisoflavone
• IPRIFLAVONE is a known antiosteoporotic agent. Its preparation is described in Hungarian patent specifications Nr. 162377 and 196981. It is known that the organism has two basic protective functions, the humoral and the cell-mediated immune responses. The so-called cell-mediated immune response is primarily directed against endogen antigens on cells infected with a virus or with an intracellular parasite, tumor cells, chemically modified cells and foreign tissues.
• T lymphocytes thymus dependent lymphocytes
• the CD4+ cells the so-called helper cells are activated upon the presentation of exogen antigens and help the immune response by increasing their cytokine production.
• the CD8+ cells the so-called cytotoxic cells are activated upon recognition of the endogen antigen then they destroy the cells recognized as foreign by cytolysis.
• peripheral lymphocytes Approximately 2/3 of the peripheral lymphocytes are CD4+ and 1/3 CD8+.
• the cytotoxic immune response is a basic protective mechanism in case of intracellular infections because by the destruction of the infected cell it eliminates the possibility for the pathogenic agent to reproduce. Similarly it has an important role in the destruction of tumor cells. In these cases the cytotoxic immune response serves to protect the integrity of the organism.
• cytotoxic immune response is undesired or even harmful.
• cytotoxic reaction is directed towards own cells of the organism causing severe functional disturbances as a result.
• Characteristic example of T cell mediated immune disease is rheumatoid arthritis.
• Pathologic cytotoxic reaction can be seen in case of certain aplastic anemias and chronic active hepatitis.
• Rejection reaction following tissue or organ transplantations is also based on the cytotoxic immune response.
• the so-called dawngraft versus host is also based on the cytotoxic reaction.
• CD4+/CD8+ ratio decreases, in certain cases reverses which is mainly the result ofthe increase of CD8+ cells and less the result ofthe decrease ofthe CD4+ cells.
• autoimmune diseases and rejection reactions following tissue/organ transplantations it is a usual treatment procedure to moderate the immune response, in certain cases even to drastically reduce it (immunosuppressive treatment).
• Immunosuppressive treatment causes not only a decrease in the number of T lymphocytes but it also has an effect toward normalization of the CD4+/CD8+ cell ratio.
• an allogen bone marrow transplant which does not contain CD8+ cell drapegraft versus host" reaction can be observed in significantly less numbers. Therefore, in the mentioned diseases a therapy that decreases specifically the number of CD8+ cells could be advantageous.
• CD8+ count was 10.43xl0 9 /l (range 0.28-0.64). Although this value is within the normal range, it falls in its lower quartilis, which finding supports the selectivite nature ofthe effect.
• CD4+ helper and CD8+ cytotoxic subgroups the average decrease was significantly different.
• the 50% CD4+ helper cell decrease, the decrease of CD8+ cytotoxic cells was 77%.
• Subject of the invention is a pharmaceutical composition suitable to decrease the number of CD8+cells comprising as active ingredient 7-isopropoxyisoflavone in admixture with suitable inert, solid or liquid carriers and optionally with usual therapeutic additives and auxiliary agents.
• suitable inert, solid or liquid carriers and optionally with usual therapeutic additives and auxiliary agents.
• the above composition can be used for the treatment of a human or animal subject
• compositions according to the invention may be prepared in the form of injection, infusion, capsule, tablet, solution, syrup, transdermal preparation, etc. by methods known per se.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Saccharide Compounds (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (2)

Family

ID=10987063

Family Applications (1)

Country Status (22)

Citations (2)

• 1995
  • 1995-07-21 HU HU9502198A patent/HU9502198D0/hu unknown
• 1996
  • 1996-07-16 PL PL96324460A patent/PL324460A1/xx unknown
  • 1996-07-16 CN CN96195722A patent/CN1191483A/zh active Pending
  • 1996-07-16 MX MX9800603A patent/MX9800603A/es unknown
  • 1996-07-16 SK SK32-98A patent/SK3298A3/sk unknown
  • 1996-07-16 WO PCT/HU1996/000038 patent/WO1997003664A1/en not_active Application Discontinuation
  • 1996-07-16 CA CA002227421A patent/CA2227421A1/en not_active Abandoned
  • 1996-07-16 KR KR1019980700235A patent/KR19990028933A/ko not_active Withdrawn
  • 1996-07-16 EA EA199800146A patent/EA199800146A1/ru unknown
  • 1996-07-16 CZ CZ9827A patent/CZ2798A3/cs unknown
  • 1996-07-16 IL IL12275196A patent/IL122751A0/xx unknown
  • 1996-07-16 BR BR9610187A patent/BR9610187A/pt not_active Application Discontinuation
  • 1996-07-16 EE EE9800020A patent/EE9800020A/xx unknown
  • 1996-07-16 EP EP96923004A patent/EP0841915A1/en not_active Withdrawn
  • 1996-07-16 JP JP50646497A patent/JP2001503371A/ja active Pending
  • 1996-07-16 AU AU63670/96A patent/AU6367096A/en not_active Abandoned
  • 1996-07-17 ZA ZA9606079A patent/ZA966079B/xx unknown
  • 1996-07-18 HR HRP9502198A patent/HRP960345A2/hr not_active Application Discontinuation
  • 1996-07-19 YU YU42796A patent/YU42796A/sh unknown
  • 1996-07-22 AR ARP960103677A patent/AR002905A1/es unknown
• 1998
  • 1998-01-12 NO NO980127A patent/NO980127D0/no unknown
  • 1998-01-14 BG BG102182A patent/BG102182A/xx unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events